DOCSLIB.ORG

Research Toward Vaccines Against Malaria

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Research Toward Vaccines Against Malaria © 1998 Nature Publishing Group http://www.nature.com/naturemedicine REVIEW Louis Miller (National Institute of Allergy and Infectious Diseases) and Stephen Hoffman (Naval Medical Research Institute) review progress toward developing malaria vaccines. They argue that multiple antigens from different stages may be needed to protect the diverse populations at risk, and that an optimal vaccine would Induce Immunity against all stages. Vaccines for African children, In whom the major mortality occurs, must induce immunity against ase,cual blood stages. Research toward vaccines against malaria Malaria is one of the major causes of the only stage of the life cycle that causes disease and death between the Tropic LOUIS H. MILLER1 disease. The stages before the asexual of Cancer and Tropic of Capricorn. & STEPHEN L. HOFFMAN2 blood stage are lumped together and Plasmodium falciparum has an especially called pre-erythrocytic. A small propor­ profound impact on infants and children in sub-Saharan Africa, tion of the asexual blood stages differentiate into sexual stages, where its effect on health is increasing as chloroquine resistance the gametocytes in red cells that infect mosquitoes; vaccines to spreads across the continent. We believe that vaccination the mosquito stages are called transmission-blocking vaccines. against P. falciparum is the intervention with the greatest poten­ The parasites' multistage life cycle and the fact that immune re­ tial to reduce malaria-associated severe morbidity and mortality sponses that recognize one stage often do not affect the next in areas with the most intense transmission and that it may do stage have made vaccine development for malaria more diffi­ so without necessarily preventing blood stage infection. Malaria cult than for antiviral and antibacterial vaccines. vaccines also would be the optimal method for preventing The pre-erythrocytic stages include sporozoites and para­ malaria in travelers to countries where malaria is transmitted. sites that develop in hepatic parenchymal cells. Sporozoites, Such vaccines will have to entirely prevent the development of after inoculation by the mosquito, spend only a few minutes any clinical manifestations of infection with P. falciparum and in the blood stream before they invade hepatocytes, in which of the second most common human malaria parasite, P. vivax. development takes a minimum of five and a half days in P. This will require preventing blood stage infection. falciparum. Antibodies to sporozoites block their infection of Infants and young children at risk from P. falciparum in Africa hepatocytes. The liver stage in rodent malarias, and probably and nonimmune travelers to areas endemic for P. falciparum and in human malarias, is attacked primarily by CDS· T cells, but P. vivax represent the extremes of target groups in whom malaria also by co4• T cells. These cells can directly eliminate the in- vaccines would be useful. Even fected cells or secrete inter­ in countries where the overall Slngea Goals Ta,vel Populallon feron (IFN)-y that induces numbers of afflicted individuals A Prevent dlJHH A Nonrnmune nitric oxide-dependent killing by blockmg "1111C · lravelen: and are not as great as in Africa, lion belofe re-nllfrom within hepatocytes. Killing all emargence ar•u of low parasites during the sporo­ malaria wreaks its havoc in from IMtr t,ansmtSSIOf\ many epidemiologic settings (o.g., lndta) zoite stage or during the he­ and population groups, dramati­ B. Reduu disease B. Ch,khn and patic infection prevents all by a "8CC11lt p,ognan1 women cally undermines the productiv­ lhal combtnes Ill.,... of high disease. Thus, stand-alone par 11ally •H• transrn.ssion ity of workers, and drains pr1t•orythrocyuc (o.g., Afnca) vaccines against pre-erythro­ national budgets. From the tnd blood suoge cytic stages are being devel- components Amazon basin to the Indian sub­ oped for protection of continent, Southeast Asia, and Reduce disuse by Chddlen and travelers. They may also have raduang blood pregnanl women a role in the general popula­ Oceania, malaria is often a major stage asuuaf ,n r&as ol high national public health problem. ~,tebu,oon transm1SSt0n tion in countries with low en- (eg., Afnca) In these settings, vaccines offer demicity such as India. Their the greatest potential for reduc­ application on their own in ing malaria's debilitating effects. areas with intense transmis­ The spread of drug-resistant P. sion is considered by some to falciparum and the recent emer­ PreYonUon or be inadvisable. There is a con­ 1rat111mls1lon cern that if the vaccines were gence and spread of chloro­ A Eradlcabon A. Vacanate enllr• quine-resistant P. vivax have community 1n too good, they would prevent IS<lltlad arou of created an increasing urgency low ltanaml&lion the development of naturally for effective malaria vaccines. B umll spread of B. Vacc,nata aa acquired anti-blood stage im­ para51tu reslSlanl combmallon with tovacc,nu blood •uoge "' munity, and if the anti-pre - p,a-e,ythrocyuc Life cycle and targets of vaccine erythrocytic immunity waned immunity ~ C. Pr..,.nl epdem• C. Vacc,nata Iha with time, the immunized ~ ,cs.,., .. of 1nbr• populalJon Understanding the life cycle I un&table malana belora lhe rains population would be left with­ (Fig. 1) of the parasite is funda­ transmlSSIOll out any immunity and could suffer an increased incidence mental to all efforts to develop Fig. 1 Multiple vaccines may need to be developed, each for a differ­ vaccines-efforts that in the ent population. Each may contain multiple antigens from one stage or of severe disease and death. end focus on reducing the ef­ combine antigens from different stages. Different formulations and This problem would be miti­ fects of the asexual blood stage, presentations may be needed for antibody or cellular immunity. gated if a pre-erythrocytic 520 NATURE MEDICINE VACCINE SUPPLEMENT • VOLUME 4 • NUMBER 5 • MAY 1998 © 1998 Nature Publishing Group http://www.nature.com/naturemedicine ·········REVIEW stage vaccine were com­ invades midgut epithelial cells. Parasites on the midgut ep­ bined with a blood stage ithelium develop into thousands of sporozoites that invade vaccine, a strategy some the salivary glands to transmit the infection while feeding on consider to be optimal. people. Transmission-blocking vaccines under development The blood stage begins contain gamete, zygote and ookinete surface proteins and se­ when parasites leave liver creted proteins from ookinetes. They induce antibodies that, cells and invade red cells. when ingested with the blood meal, block fertilization, de­ The parasite develops and velopment, penetration of the peritrophic membrane or in­ j multiplies within the red vasion of midgut epithelium. Such vaccines would block ! cell; 16 or more merozoites transmission of mutant parasites resistant to drugs or to vac­ j appear 48 hours after inva­ cines against other stages. Furthermore, they could be used " sion (in P. falciparum and P. for epidemic control in areas of unstable transmission. The f vivax). The infected red cell third use, in combination with other interventions such as .u lyses, releasing merozoites, insecticides, would be for malaria eradication in island com­ Human red cells infected with each capable of invading munities (such as Sri Lanka) where transmission is low. Plasmodium falciparum. other red cells. The para­ Several constructs that contain a surface protein on sitemia can increase ten-fold ookinetes, Pfs25, are under development and are being tested each 48 hours. No disease occurs until the parasitemia in normal volunteers. reaches a level critical for induction of fever and shaking Unlike most viral vaccines, malaria vaccines will be pro­ chills. The serious complications of anemia and coma ap­ duced as subunits that will contain only a few of the esti­ pear later in the infection as the parasitemia rises. The cur­ mated 5,000-7,000 proteins in the parasite or parts of these rent vaccine approach is to design blood stage vaccines that proteins. Below, we identify obstacles to successful subunit will prime the individual for boosting of immunity by the vaccine development for pre-erythrocytic and blood stage parasite during each infection, thereby controlling para­ vaccines and present our perspective on how to overcome sitemia before serious complications occur. There are data them. For those interested in the details of antigens and indicating that disease in young children in Africa is influ­ strategies for vaccine development, see refs. 4 & 5. enced by the intensity of transmission (number of infectious bites per year), the child's genetics, and perhaps virulence Pre-erythrocytic stage vaccines factors in P. falciparum 1• For example, in many areas, cere­ Immunization of mice and humans with radiation-attenu­ bral malaria (coma and seizures with high mortality) is un­ ated sporozoites of rodent and human malaria parasites, re­ common before two years of age2• In low-transmission areas spectively, induces complete protection against the (< 15 bites/individual by infected mosquitoes per year), se­ pathologic and clinical manifestations of the infection. The vere anemia occurs early in life and cerebral malaria later, protective immunity prevents the parasites from emerging suggesting a developmental susceptibility to cerebral from the liver into the bloodstream, is not strain specific, malaria in children2 • In high-transmission areas (> 100 and lasts in humans for at least nine months (ref. 6 for re­ bites/individual by infected
Load more

Recommended publications
  • RTS,S Malaria Vaccine First Malaria Vaccine Will Be Piloted in Areas of Three African Countries Through Routine Immunization Programs
    CENTER FOR VACCINE INNOVATION AND ACCESS The RTS,S malaria vaccine First malaria vaccine will be piloted in areas of three African countries through routine immunization programs Summary the vaccine’s role in reducing childhood deaths and severe malaria, and its safety in the context of routine use. Data and Malaria kills more than 400,000 people a year worldwide and information from the MVIP will inform a WHO policy causes illness in tens of millions more, with most deaths recommendation on the broader use of the vaccine. RTS,S has occurring among young children living in sub-Saharan Africa. been approved for use in the pilot evaluation and Phase 4 Although existing interventions have helped to reduce malaria studies by the national regulatory authority in each of the three deaths significantly over the past 15 years, a vaccine could add participating countries. an important complementary tool for malaria control efforts. Financing for the MVIP has been mobilized through an RTS,S/AS01 (RTS,S) is the first malaria vaccine shown to unprecedented collaboration among three global health funding provide partial protection against malaria in young children. It bodies: Gavi, the Vaccine Alliance; the Global Fund to Fight will be the first malaria vaccine provided to young children AIDS, Tuberculosis and Malaria; and Unitaid. Additionally, through national immunization programs in three sub-Saharan WHO, PATH, and GSK are providing in-kind contributions, African countries—Ghana, Kenya, and Malawi. These countries which include GSK’s donation of the vaccine for use in the will introduce the vaccine in selected areas as part of a large- MVIP.
    [Show full text]
  • I Raise the Rates! April Edition
    I Raise the Rates! - April Edition I Raise the Rates! April Edition In this edition of I Raise the Rates (IRtR) you will find a variety of new resources from various public health partners, unique education opportunities, and a brief selection of popular media articles related to immunization. Updates from the American College of Physicians (ACP) Opportunity to Participate in ACP Quality Improvement Initiative to Increase Adult Influenza Immunization Rates APPLY NOW - Opportunity to participate in ACP's Quality Improvement Initiative to Increase Adult Influenza Immunization Rates. ACP is recruiting internal medicine and subspecialty practices and residency programs to participate in the I Raise the Rates quality improvement programs to increase influenza and adult immunization rates. ACP’s I Raise the Rates program, which is supported by funding from the CDC, Merck, and GSK, provides QI education and virtual coaching support from ACP Advance expert coaches to support increased adult immunization coverage. The program also offers access to a virtual learning community, tailored educational offerings, and the opportunity to earn more than 54 CME and ABIM MOC credits for program participants. Onboarding is underway so act now! Opportunity is limited, applicants will be considered on a first-come, first-served basis. Please see the attached recruitment flyer for more information about participation benefits and requirements as well as the application link. https://myemail.constantcontact.com/I-Raise-the-Rates----April-Edition---Layout-Template.html?soid=1124874283215&aid=uMyKdB7UvYQ 1/6 I Raise the Rates! - April Edition View the Flyer by Clicking Here ACP COVID-19 Vaccine Forum IV, Practical Clinical Considerations ACP COVID-19 Vaccine Forum IV, Practical Clinical Considerations was the forth in a series of vaccine forums hosted by ACP and Annals of Internal Medicine and was held on March 24, 2021.
    [Show full text]
  • Downloaded from Uniprotkb 667 (UP000005640.Fasta)
    medRxiv preprint doi: https://doi.org/10.1101/2021.07.21.21260959; this version posted July 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 1 Title page 2 Proteomic and metabolomic signatures associated with the immune response in 3 healthy individuals immunized with an inactivated SARS-CoV-2 vaccine 4 5 Yi Wang,1,#,* Xiaoxia Wang,2,# Laurence Don Wai Luu,3,# Shaojin Chen2, Fu Jin,1 6 Shufang Wang,4 Xiaolan Huang,1 Licheng Wang,2 Xiaocui Zhou,2 Xi Chen,2 Xiaodai 7 Cui,1 Jieqiong Li,5,* Jun Tai,6,* and Xiong Zhu2,* 8 9 1 Experimental Research Center, Capital Institute of Pediatrics, Beijing, 100020, P.R. 10 China 11 2 Central & Clinical Laboratory of Sanya People’s Hospital, Sanya, Hainan 572000, P. 12 R. China. 13 3 School of Biotechnology and Biomolecular Science, University of New South Wales, 14 Sydney, Australia 15 4 Nursing department of Sanya People’s Hospital, Sanya, Hainan 572000, P. R. China. 16 5 Department of Respiratory Disease, Beijing Pediatric Research Institute, Beijing 17 Children’s Hospital, Capital Medical University, National Center for Children’s 18 Health, Beijing 10045, P. R. China 19 6 Department of Otolaryngology, Head and Neck Surgery, Children's Hospital Capital 20 Institute of Pediatrics, Beijing 100020, P. R. China. 21 22 # These authors contributed equally 23 24 25 * Correspondence: 26 Dr.
    [Show full text]
  • Meeting Report
    Meeting Report EXPERT CONSULTATION ON PLASMODIUM KNOWLESI MALARIA TO GUIDE MALARIA ELIMINATION STRATEGIES 1–2 March 2017 Kota Kinabalu, Malaysia Expert Consultation on Plasmodium Knowlesi Malaria to Guide Malaria Elimination Strategies 1–2 March 2017 Kota Kinabalu, Malaysia WORLD HEALTH ORGANIZATION REGIONAL OFFICE FOR THE WESTERN PACIFIC RS/2017/GE/05/(MYS) English only MEETING REPORT EXPERT CONSULTATION ON PLASMODIUM KNOWLESI MALARIA TO GUIDE MALARIA ELIMINATION STRATEGIES Convened by: WORLD HEALTH ORGANIZATION REGIONAL OFFICE FOR THE WESTERN PACIFIC Kota Kinabalu, Malaysia 1–2 March 2017 Not for sale Printed and distributed by: World Health Organization Regional Office for the Western Pacific Manila, Philippines September 2017 NOTE The views expressed in this report are those of the participants of the Expert Consultation on Plasmodium knowlesi Malaria to Guide Malaria Elimination Strategies and do not necessarily reflect the policies of the World Health Organization. This report has been prepared by the World Health Organization Regional Office for the Western Pacific for governments of Member States in the Region and for those who participated in the Expert Consultation on Plasmodium knowlesi Malaria to Guide Malaria Elimination Strategies, which was held in Kota Kinabalu, Malaysia from 1 to 2 March 2017. CONTENTS ABBREVIATIONS SUMMARY 1. INTRODUCTION ............................................................................................................................................. 1 2. PROCEEDINGS ...............................................................................................................................................
    [Show full text]
  • Unexpected Fold in the Circumsporozoite Protein Target of Malaria Vaccines
    Unexpected fold in the circumsporozoite protein target of malaria vaccines Michael B. Doud, Adem C. Koksal, Li-Zhi Mi, Gaojie Song, Chafen Lu, and Timothy A. Springer1 Immune Disease Institute, Children’s Hospital Boston and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115 Contributed by Timothy A. Springer, April 4, 2012 (sent for review March 19, 2012) Circumsporozoite (CS) protein is the major surface component of Plas- The CS structures reveal a unique “αTSR” domain that is modium falciparum sporozoites and is essential for host cell invasion. related to TSR domains yet has unique features (Figs. 1 C and D A vaccine containing tandem repeats, region III, and thrombospondin and 2). Region III forms an integral part of the fold as a unique type-I repeat (TSR) of CS is efficacious in phase III trials but gives only amphipathic α-helix running orthogonally to the classic three- a 35% reduction in severe malaria in the first year postimmunization. stranded TSR homology region. This α1-helix, together with We solved crystal structures showing that region III and TSR fold into a “CS flap” (Fig. 1 C and D), decorates one face of the TSR asingleunit,an“αTSR” domain. The αTSR domain possesses a hydro- β-sheet (Fig. 2A). By packing against the β-sheet, the region III phobic pocket and core, missing in TSR domains. CS binds heparin, but α-helix gives the αTSR domain a hydrophobic core lacking in αTSR does not. Interestingly, polymorphic T-cell epitopes map to spe- TSR domains. A short linker containing a conserved hydro- cialized αTSR regions.
    [Show full text]
  • Proposed Integrated Control of Zoonotic Plasmodium Knowlesi in Southeast Asia Using Themes of One Health
    Tropical Medicine and Infectious Disease Review Proposed Integrated Control of Zoonotic Plasmodium knowlesi in Southeast Asia Using Themes of One Health Jessica Scott College of Public Health and Medical and Veterinary Sciences, Australian Institute of Tropical Health and Medicine, James Cook University, Townsville 4811, Australia; [email protected] Received: 25 September 2020; Accepted: 18 November 2020; Published: 20 November 2020 Abstract: Zoonotic malaria, Plasmodium knowlesi, threatens the global progression of malaria elimination. Southeast Asian regions are fronting increased zoonotic malaria rates despite the control measures currently implemented—conventional measures to control human-malaria neglect P. knowlesi’s residual transmission between the natural macaque host and vector. Initiatives to control P. knowlesi should adopt themes of the One Health approach, which details that the management of an infectious disease agent should be scrutinized at the human-animal-ecosystem interface. This review describes factors that have conceivably permitted the emergence and increased transmission rates of P. knowlesi to humans, from the understanding of genetic exchange events between subpopulations of P. knowlesi to the downstream effects of environmental disruption and simian and vector behavioral adaptations. These factors are considered to advise an integrative control strategy that aligns with the One Health approach. It is proposed that surveillance systems address the geographical distribution and transmission clusters of P. knowlesi and enforce ecological regulations that limit forest conversion and promote ecosystem regeneration. Furthermore, combining individual protective measures, mosquito-based feeding trapping tools and biocontrol strategies in synergy with current control methods may reduce mosquito population density or transmission capacity. Keywords: Zoonotic diseases; Integrated vector management; vector-borne disease; One Health 1.
    [Show full text]
  • Renal Localization of Plasmodium Vivax and Zoonotic Monkey Parasite Plasmodium Knowlesi Derived Components in Malaria Associated Acute Kidney Injury
    bioRxiv preprint doi: https://doi.org/10.1101/544726; this version posted May 3, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Renal Localization of Plasmodium vivax and Zoonotic Monkey Parasite Plasmodium knowlesi Derived Components in Malaria Associated Acute Kidney Injury Pragyan Acharya1#, Atreyi Pramanik1*, Charandeep Kaur1*, Kalpana Kumari2*, Rajendra Mandage1, Amit Kumar Dinda2, Jhuma Sankar3, Arvind Bagga3, Sanjay Kumar Agarwal4, Aditi Sinha3, Geetika Singh2 *These authors have contributed equally # Corresponding Author: [email protected] (Lab 3002, Department of Biochemistry, 3rd Floor, Teaching Block, AIIMS, Ansari Nagar, New Delhi – 110029) Author Affiliations: 1 Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India 2Department of Pathology, All India Institute of Medical Sciences, New Delhi, India 3Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India 4Department of Nephrology, All India Institute of Medical Sciences, New Delhi, India 1 bioRxiv preprint doi: https://doi.org/10.1101/544726; this version posted May 3, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. ABSTRACT Objectives Acute kidney injury (AKI) is a frequent clinical manifestation of severe malaria. Although the pathogenesis of P. falciparum severity is attributed to cytoadherence, the pathogenesis due to P.
    [Show full text]
  • (PPC) for Malaria Vaccines
    WHO/IVB/14.09 WHO Preferred Product Characteristics (PPC) for Malaria Vaccines DEPARTMENT OF IMMUNIZATION, VACCINES AND BIOLOGICALS Family, Women’s and Children’s Health (FWC) WHO/IVB/14.09 WHO Preferred Product Characteristics (PPC) for Malaria Vaccines DEPARTMENT OF IMMUNIZATION, VACCINES AND BIOLOGICALS Family, Women’s and Children’s Health (FWC) The Department of Immunization, Vaccines and Biologicals thanks the donors whose unspecified financial support has made the production of this document possible. This document was produced by the Initiative for Vaccine Research (IVR) of the Department of Immunization, Vaccines and Biologicals Ordering code: WHO/IVB/14.09 Published: November 2014 This publication is available on the Internet at: www.who.int/vaccines-documents/ Copies of this document as well as additional materials on immunization, vaccines and biologicals may be requested from: World Health Organization Department of Immunization, Vaccines and Biologicals CH-1211 Geneva 27, Switzerland • Fax: + 41 22 791 4227 • Email: [email protected] • © World Health Organization 2014 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 3264; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
    [Show full text]
  • Expres2ion Biotech Holding Sponsored Research Initiating Coverage 24 June 2021
    ExpreS2ion Biotech Holding Sponsored Research Initiating Coverage 24 June 2021 Rising to the COVID-19 challenge ExpreS2ion Biotech is a contract research organization, which has been founded over 10 years ago. The company specializes in the production of complex proteins using its proprietary protein Target price (SEK) 60 expression platform. More recently, the company has been focusing Share price (SEK) 36 on the development of its pipeline, which includes several vaccine and therapeutic candidates. Out of this group, we regard the Forecast changes ABNCoV2 project (COVID-19 vaccine), carrying the highest near- % 2021e 2022e 2023e term potential. Its partner, Bavarian Nordic, plans to start Phase III Revenues NM NM NM trial later this year, pending funding. We expect an upward EBITDA NM NM NM EBIT adj NM NM NM potential rerating of SEK 50 per share, should the vaccine EPS reported NM NM NM successfully go through clinical development and receive regulatory EPS adj NM NM NM approval. We initiate coverage of ExpreS2ion Biotech with a Buy Source: Pareto rating, target price SEK 60 per share. Ticker EXPRS2.ST, EXPRS2 SS Sector Healthcare COVID-19 vaccine project carries the highest near-term potential Shares fully diluted (m) 27.6 Market cap (SEKm) 988 Despite the rapid success of a number of COVID-19 vaccines, there is Net debt (SEKm) -114 a need for improved vaccines that offer strong immunogenicity as Minority interests (SEKm) 0 well as ease of clinical administration, stability and adaptiveness of Enterprise value 21e (SEKm) 938 platform. Given impressive pre-clinical results, as well as solid interim Free float (%) 83 Phase I safety data, we believe ABNCoV2 has a significant opportunity to succeed through the rest of clinical development.
    [Show full text]
  • Indel-Informed Bayesian Analysis Suggests Cryptic Population
    Infection, Genetics and Evolution 75 (2019) 103994 Contents lists available at ScienceDirect Infection, Genetics and Evolution journal homepage: www.elsevier.com/locate/meegid Research Paper Indel-informed Bayesian analysis suggests cryptic population structure between Plasmodium knowlesi of humans and long-tailed macaques (Macaca T fascicularis) in Malaysian Borneo ⁎ JustinJ.S. Wilcox ,1, Abigail Kerschner, Hope Hollocher Department of Biological Sciences, University of Notre Dame, Notre Dame, IN 46556-5688, USA ARTICLE INFO ABSTRACT Keywords: Plasmodium knowlesi is an important causative agent of malaria in humans of Southeast Asia. Macaques are Malaria natural hosts for this parasite, but little is conclusively known about its patterns of transmission within and Plasmodium knowlesi between these hosts. Here, we apply a comprehensive phylogenetic approach to test for patterns of cryptic Zoonosis population genetic structure between P. knowlesi isolated from humans and long-tailed macaques from the state Macaque of Sarawak in Malaysian Borneo. Our approach differs from previous investigations through our exhaustive use Host specificity of archival 18S Small Subunit rRNA (18S) gene sequences from Plasmodium and Hepatocystis species, our inclusion Phylogeny of insertion and deletion information during phylogenetic inference, and our application of Bayesian phyloge- netic inference to this problem. We report distinct clades of P. knowlesi that predominantly contained sequences from either human or macaque hosts for paralogous A-type and S-type 18S gene loci. We report significant partitioning of sequence distances between host species across both types of loci, and confirmed that sequences of the same locus type showed significantly biased assortment into different clades depending on their host species.
    [Show full text]
  • Professor Salimata Thurston Née Wade
    2010 Winner of AU-ECOWAS Women Scientists Award Life Sciences and Earth Professor Salimata Thurston née Wade Mrs. Salimata Thurston née Wade is a top-notch tenured Professor of Physiology and Human Nutrition at the Faculty of Sciences and Technology of Université Cheikh Anta Diop, Dakar (UCAD). She was Head of Department of Animal Biology of the FST, UCAD from 2004 to 2006 and currently serves as Director of the Nutrition Laboratory and is in charge of doctoral training at the Ecole Doctorale ED-SEV of UCAD. Born in Dakar, at the Médina, on 28 February 1951, Mrs. Wade completed her primary education in Dakar and continued with secondary education at the Lycée Carnot School for Young Girls later known as Lycée John F. Kennedy. She obtained her baccalauréat D with honours in 1972. She continued her education in France at the Université Paris 7 and specialized in Physiology and General Human Biology, with focus on Nutrition. In 1978, she joined INSERM’s prestigious Unit 1 for Research in Nutrition of the Bichat Hospital. Mrs Wade would spend 9 years there in order to carry out research, particularly on biological signs of malnutrition and effects of interplay between malnutrition and infection. In 1986, Mrs Wade defended her Doctoral thesis on the theme “Transthyretin (Prealbumine) and Thymuline (Zn-FTS) in Protein- Energy Malnutrition” at the Université Paris 7. She was awarded High Honours by the jury. She also underwent several internships in various laboratories, such as Dunn Nutrition Laboratory of the Medical Research Council (HNR) o f Cambridge, England in order to specialise in the measurement of energy expenditure in men and the use of stable isotopes in nutrition.
    [Show full text]
  • En Este Número
    Boletín Científico No. 18 (1-10 julio/2021) EN ESTE NÚMERO VacCiencia es una publicación dirigida a Resumen de candidatos vacu- investigadores y especialistas dedicados a nales contra la COVID-19 ba- la vacunología y temas afines, con el ob- sadas en la plataforma de sub- jetivo de serle útil. Usted puede realizar unidad proteica en desarrollo a sugerencias sobre los contenidos y de es- nivel mundial. (segunda parte) ta forma crear una retroalimentación Artículos científicos más que nos permita acercarnos más a sus recientes de Medline sobre necesidades de información. vacunas. Patentes más recientes en Patentscope sobre vacunas. Patentes más recientes en USPTO sobre vacunas. 1| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS Resumen de vacunas contra la COVID-19 basadas en la plataforma de subunidad proteica en desarrollo a nivel mundial (segunda parte) Las vacunas de subunidades antigénicas son aquellas en las que solamente se utilizan los fragmentos específicos (llamados «subunidades antigénicas») del virus o la bacteria que es indispensable que el sistema inmunitario reconozca. Las subunidades antigénicas suelen ser proteínas o hidratos de carbono. La mayoría de las vacunas que figuran en los calendarios de vacunación infantil son de este tipo y protegen a las personas de enfermedades como la tos ferina, el tétanos, la difteria y la meningitis meningocócica. Este tipo de vacunas solo incluye las partes del microorganismo que mejor estimulan al sistema inmunitario. En el caso de las desarrolladas contra la COVID-19 contienen generalmente, la proteína S o fragmentos de la misma como el Dominio de Unión al Receptor (RBD, por sus siglas en inglés).
    [Show full text]